MS4A2

MS4A2 encodes the FcεRIβ chain of the high-affinity IgE receptor expressed on mast cells, where its expression is required for cell-surface FcεRI display and IgE-mediated degranulation (PMID:24639354). Transcription is driven by GATA2, which binds the proximal MS4A2 promoter and directly transactivates the gene; GATA2 knockdown lowers FcεRIβ mRNA and suppresses IgE-triggered degranulation (PMID:24639354). GATA2 acts together with PU.1 through distinct but cooperative mechanisms: GATA2 binds the proximal −60-bp promoter in a mast cell-specific manner, while both GATA2 and PU.1 occupy a +10.4-kbp downstream enhancer alongside the chromatin-looping factor LDB1, with PU.1 establishing active chromatin that enables GATA2 access; deletion of the +10.4-kbp enhancer abolishes both Ms4a2 expression and surface FcεRI (PMID:31501274). A common −109T/C promoter polymorphism modulates MS4A2 promoter activity, with the −109T allele conferring higher transcriptional activity (PMID:16839402). Beyond this transcriptional control of FcεRIβ in mast cells, the protein's own signaling biochemistry is not characterized in the available corpus.

1. 2006 Medium

   Whether sequence variation in the MS4A2 promoter functionally alters its transcription was unknown; this established that the −109T allele drives higher promoter activity than the −109C allele.

   Evidence Luciferase reporter assays comparing alleles in RBL-2H3 and A549 cell lines

   PMID:16839402

   Open questions at the time

   • Single method type in one lab
   • No endogenous chromatin or transcription factor binding context for the variant
   • Functional consequence for FcεRI surface expression not tested
2. 2009 Low

   To test whether the promoter genotype predicts transcript abundance in vivo, this correlated the −109T allele with reduced FcεRIβ mRNA in human peripheral blood.

   Evidence mRNA quantification correlated with promoter genotype in human subjects

   PMID:19218813

   Open questions at the time

   • Single small cohort (15 individuals), no functional reconstitution
   • Direction relative to reporter findings not mechanistically reconciled
   • No causal manipulation
3. 2014 High

   The trans-acting factor controlling MS4A2 was unresolved; this identified GATA2 as a direct transcriptional activator whose loss impairs FcεRI-driven mast cell function.

   Evidence ChIP, EMSA, luciferase reporter, and siRNA knockdown with degranulation readout in human LAD2 mast cells

   PMID:24639354

   Open questions at the time

   • Cooperating factors and distal regulatory elements not yet defined
   • Mechanism of mast cell-specific promoter selection unaddressed
4. 2019 High

   How GATA2 achieves mast cell-specific, locus-wide activation was unknown; this resolved a two-element architecture in which GATA2 binds the proximal promoter while GATA2/PU.1/LDB1 cooperate at an essential +10.4-kbp enhancer.

   Evidence ChIP, genome-editing deletion of the +10.4-kbp enhancer, and siRNA in mouse mast cells with FcεRI surface readout

   PMID:31501274

   Open questions at the time

   • Direct LDB1-mediated loop topology not structurally resolved
   • Human enhancer equivalence to mouse +10.4-kbp element not established
   • Integration with −109 promoter variant unexplored
5. 2023 Low

   Whether MS4A2 marks functionally distinct mast cell states in disease was unaddressed; this localized MS4A2-high tumor-associated mast cells and correlated them with bidirectional chemokine regulation in lung adenocarcinoma.

   Evidence Single-cell and bulk RNA-seq with immune infiltration analysis

   PMID:40607924

   Open questions at the time

   • Computational/transcriptomic only, no functional test of MS4A2 protein activity
   • Causal role of MS4A2 in chemokine output not demonstrated
   • Single study

• The signaling biochemistry of the FcεRIβ protein itself — its partners, membrane assembly, and contribution to receptor signal amplification — remains uncharacterized in this corpus.
• No direct protein-level interaction or signaling data in the timeline
• No structural model of the receptor complex